PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Onward Medical N.v.

USPTO PatentsView assignee record - 27 granted patents across 9 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Explore the portfolio See the ranking
27
Total patents granted
9
CPC technology areas
11.8
Avg claims per patent
-
5-year filing velocity

The verdict

Onward holds 27 US patents across 9 technology areas, rank #11,377 of 50,000 tracked assignees.

#11,377
of 50,000 US assignees by volume
Top 15%
by Innovation Score (49.2/100)
11.8
avg claims per patent

Portfolio overview

Onward Medical N.V. has been granted 27 US utility patents between 2022 and 2025, placing Onward Medical N.V. at rank #11,377 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.8 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Onward Medical N.V. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 49.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 27 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Onward Medical N.V.'s 11.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Onward Medical N.V. against peers pursuing similar technology classes.

How does Onward compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Onward holds 27 patents, placing it at rank #11,377 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Onward's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

246810 2022202320242025 4
USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table
Onward Medical N.V. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2022 9 33.3%
2023 9 33.3%
2024 5 18.5%
2025 4 14.8%

Which technologies does Onward Medical N.V. patent most?

Top 9 of 9 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple

Where it ranks

Overall rank by patents

#11,377

Across all tracked assignees

Innovation Score

49.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Onward Medical N.V. hold?
Onward Medical N.V. holds 27 US granted patents filed between 2022 and 2025, spanning 9 technology areas.
What is Onward Medical N.V.'s Innovation Score?
Onward Medical N.V. has an Innovation Score of 49.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Onward Medical N.V. focus on?
Onward Medical N.V.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 20 patents. The company has filed patents in 9 CPC subclasses total.
Is Onward Medical N.V.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Onward Medical N.V..
What does claim depth mean for Onward Medical N.V.'s patents?
Onward Medical N.V.'s patents average 11.8 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Onward Medical N.V. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Onward's 27 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Onward ranks #11,377 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61N technology

Onward Medical N.V.'s primary CPC class, all holders and yearly trends
Top 50 patent holders

See where Onward Medical N.V. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov